STOCK TITAN
  1. Home
  2. Sec-filings
  3. CALC
  4. [8-K] CalciMedica, Inc. Reports Material Event

CalciMedica regains Nasdaq equity bar, bid risk

Even after its 1-for-5 reverse split took effect Aug. 28, CalciMedica still has no assurance it will regain Nasdaq’s $1.00 minimum bid compliance.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reports an update on its Nasdaq listing status. After previously falling below Nasdaq’s $35,000,000 market value of listed securities requirement, Nasdaq has now determined that CalciMedica satisfies the alternative stockholders’ equity standard under Listing Rule 5550(b)(1), based on reported equity of $5,513,000 as of June 30, 2026. This closes the prior deficiency related to market value of listed securities.

The company remains out of compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Listing Rule 5550(a)(2). CalciMedica has until September 14, 2026 to regain compliance. A one-for-five reverse stock split of its common stock became effective at 5:00 p.m. Eastern Time on August 28, 2026, but there is no assurance the company will meet the minimum bid price or maintain overall listing compliance.

Positive

  • Nasdaq MVLS deficiency cured via equity standard: Nasdaq determined CalciMedica now complies with Listing Rule 5550(b)(1) based on $5,513,000 of stockholders’ equity reported as of June 30, 2026, closing the earlier non-compliance related to the $35,000,000 market value of listed securities requirement.

Negative

  • Ongoing Nasdaq minimum bid price deficiency: CalciMedica remains below the $1.00 Minimum Bid Price Requirement, with a compliance deadline of September 14, 2026, and explicitly notes there can be no assurance it will regain compliance or maintain other listing requirements despite a recent one-for-five reverse stock split.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Stockholders’ equity $5,513,000 Reported in Form 10-Q for the quarter ended June 30, 2026; used to satisfy Nasdaq Listing Rule 5550(b)(1)
Nasdaq MVLS minimum requirement $35,000,000 Minimum market value of listed securities under Nasdaq Listing Rule 5550(b)(2)
Minimum Bid Price Requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) threshold for CalciMedica’s common stock
Compliance deadline for MVLS notice September 9, 2026 End of 180-day period to regain compliance with the MVLS Requirement after March 13, 2026 notice
Compliance deadline for Minimum Bid Price September 14, 2026 End of 180-day period to regain compliance with Nasdaq Minimum Bid Price Requirement after March 16, 2026 notice
Reverse stock split ratio 1-for-5 One-for-five reverse stock split of outstanding common stock effective August 28, 2026
Consecutive business days below thresholds 30 days Period during which market value of listed securities and minimum bid price were each below Nasdaq requirements before respective notices
market value of listed securities market
"the market value of listed securities (the “MVLS Requirement”)"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
Nasdaq Listing Rule 5550(b)(1) regulatory
"alternative minimum stockholders’ equity requirement set forth under Nasdaq Listing Rule 5550(b)(1)"
Nasdaq Listing Rule 5550(b)(2) regulatory
"not in compliance with Nasdaq’s Listing Rule 5550(b)(2)"
Minimum Bid Price Requirement market
"below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
reverse stock split financial
"implemented a one-for-five reverse stock split of its outstanding common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

What Nasdaq compliance issue did CalciMedica (CALC) resolve in this 8-K?
CalciMedica resolved its deficiency with Nasdaq’s market value of listed securities requirement. Nasdaq determined the company now complies with the alternative stockholders’ equity standard under Listing Rule 5550(b)(1), based on reported equity of $5,513,000 as of June 30, 2026.

What is CalciMedica’s stockholders’ equity cited for Nasdaq compliance?
CalciMedica reported $5,513,000 of stockholders’ equity in its Form 10-Q for the quarter ended June 30, 2026. Nasdaq’s staff relied on this figure to conclude the company meets the alternative stockholders’ equity standard under Listing Rule 5550(b)(1).

Is CalciMedica (CALC) now fully compliant with all Nasdaq requirements?
No. While the market value of listed securities deficiency is closed, CalciMedica remains out of compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Listing Rule 5550(a)(2) and states there is no assurance it will regain or maintain full compliance.

What deadline does CalciMedica face to fix the Nasdaq minimum bid price issue?
CalciMedica has until September 14, 2026 to regain compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement. This 180-day period runs from the March 16, 2026 notice that the company’s common stock traded below $1.00 for 30 consecutive business days.

What reverse stock split did CalciMedica implement and when?
CalciMedica implemented a one-for-five reverse stock split of its outstanding common stock effective at 5:00 p.m. Eastern Time on August 28, 2026. The reverse split was part of its efforts related to Nasdaq’s Minimum Bid Price Requirement.

What was the original Nasdaq market value of listed securities requirement for CALC?
CalciMedica had fallen below Nasdaq’s $35,000,000 minimum market value of listed securities requirement under Listing Rule 5550(b)(2) for 30 consecutive business days, triggering the earlier deficiency notice that has now been closed via the equity-based alternative standard.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NASDAQ false 0001534133 0001534133 2026-08-31 2026-08-31
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 31, 2026

Date of Report (Date of earliest event reported)

 

 

CalciMedica, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39538   45-2120079

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

505 Coast Boulevard South, Suite 307
La Jolla, California		   92037
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 952-5500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001, par value per share   CALC   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01

Other Events.

Market Value of Listed Securities

As previously disclosed, on March 13, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS Requirement”) for the Company’s common stock had been below the minimum MVLS Requirement of $35,000,000 for the last 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(C), the Company had 180 calendar days following the date of the notice, or until September 9, 2026, to regain compliance.

On August 31, 2026, the Company received a letter from the Staff stating that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of $5,513,000, and the Company’s submissions to the Staff, the Staff determined that the Company complies with the alternative minimum stockholders’ equity requirement set forth under Nasdaq Listing Rule 5550(b)(1). Accordingly, the Notice and the Company’s non-compliance with the MVLS Requirement is now closed.

Minimum Bid Price

As previously disclosed, on March 16, 2026, the Company received a notice from the Staff that the Company was not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The Company has not yet regained compliance with the Minimum Bid Price Requirement and has 180 calendar days following the date of the notice, or until September 14, 2026, to regain compliance with the Minimum Bid Price Requirement. As previously disclosed, at 5:00 p.m. (Eastern Time) on August 28, 2026, the Company implemented a one-for-five reverse stock split of its outstanding common stock.

There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with the other listing requirements.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CalciMedica, Inc.
Date: September 2, 2026     By:  

/s/ A. Rachel Leheny, Ph.D.

    Name:   A. Rachel Leheny, Ph.D.
    Title:   Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents